Repligen stock
Price history
+11.00% over the period1 year: from $149.00 (November 17, 2025) to $165.39 (November 16, 2026), +11.00%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $165.39 |
| October 30, 2026 | $176.94 |
| September 30, 2026 | $192.23 |
| August 31, 2026 | $180.98 |
| July 31, 2026 | $141.01 |
| June 30, 2026 | $136.44 |
| May 29, 2026 | $123.95 |
| April 30, 2026 | $118.31 |
| March 31, 2026 | $117.82 |
| February 27, 2026 | $128.73 |
| January 30, 2026 | $149.37 |
| December 31, 2025 | $163.86 |
| November 28, 2025 | $171.02 |
| November 17, 2025 | $149.00 |
At a glance
The company
Develops and commercializes bioprocessing technologies and systems for biopharmaceutical, life sciences and diagnostics companies
Latest results
Quarter to September 30, 2026 · EPS $0.53 (estimate $0.46)
TickerLandia's take on Repligen
- Priced as usual relative to earnings: P/E on the latest fiscal year 192 vs a median of 173 over its last 5 fiscal years.
- Strong point: Market momentum (70/100 in its group). Weak point: Earnings stability (13/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−16.84% from the 52-week high
Analysts · 20 analysts
Average target$203.21+22.87% vs. price
Buy 16 · Hold 4 · Sell 0 · Buy
TickerLandia Fingerprint: Repligen
Compared with similar companies: very low earnings stability, very high price, and very low profitability.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high85
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 68.7 93 EV/EBITDA 73.6 96 Price/book 4.88 60 Price/sales 12.6 93 Profitabilityvery low20
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 53.8% 49 Net margin −1.5% 10 ROE −0.6% 10 ROA 1.4% 4 Operating margin 8.1% 25 Earnings stabilityvery low13
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 18 Margin variabilitycounts in reverse: lower means more earnings stability 13.9% 7 Growthlow35
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −2.70% 16 Revenue growth (year over year) +10.86% 84 Earnings growth (year over year) −361.54% 5 Financial strengthaverage53
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 1.97 8 Debt/equitycounts in reverse: lower means more financial strength 0.33 59 Current ratio 9.88 99 Net debt/EBITDAcounts in reverse: lower means more financial strength 1.00 47 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong70
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +54.33% 96 1-year return +11.44% 47 Distance from 200-day average +15.51% 82 Relative strength (3 months) +3.32% 56 Riskhigh73
How much the price swings.
Metric Value Position in group Beta (1 year) 1.23 71 Volatility (60 days) 48.8% 75 Maximum drawdown (12 months) 40.3% 74
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Repligen is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Repligen's P/E today is 192.3, in line with the median of its last 5 fiscal years (172.6; between 52.3 and 285.4 from 2020 to 2025). Repligen's Forward P/E: 63.3, +261% against the median of a group of 11 similar companies (17.5).
Compared with 11 similar companies
| Metric | Repligen | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 63.3 | High | |
| Operating margin | 8.1% | Middle | |
| ROE | -0.6% | Low | |
| Debt/equity | 0.33 | Middle | |
| Price/book | 4.55 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Repligen. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$209.31M
Latest quarter · Q3 2026
Net income
-$38.43M
Latest quarter · Q3 2026
Quarterly net margin
-18.4%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $10.73B
- EPS
- -$0.21
- Volume
- 510.11K
- Daily trading
- €200.93M
- Dividend yield
- 0.00%
How Repligen is changing
All resultsRevenue grew 15.0% a year on average over the last 5 years
Operating margin fell from 28.0% to 7.5%
Shares outstanding up 5.0% in 5 years
Returns
Repligen returns
$1,000 invested in Repligen 5 years ago, on November 16, 2021, would be worth $615 today: −38.51% in total, −9.27% per year. This is the price return only: dividends are excluded.
| Period | Repligen | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −5.72% | −3.12% | $943 |
| 6 months | +60.78% | +2.07% | $1,608 |
| Year to date | +0.93% | +10.46% | $1,009 |
| 1 year | +11.00% | +13.33% | $1,110 |
| 3 years | +9.16% | +67.73% | $1,092 |
| 5 years | −38.51% | +60.86% | $615 |
| 10 years | +416.36% | +247.35% | $5,164 |
Over the last 6 months it has done better than 92% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Repligen: technical analysis
Repligen shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 49.0% below its highest close since January 2, 1990 ($324.21, September 23, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 42
- Between 30 and 70
- vs 200-session average
- +13.79%
Support and resistance
Price areas where Repligen has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$188.59+14.03%3 touches, last on October 29, 2026
- Resistance$174.88+5.74%3 touches, last on January 22, 2026
- Last price$165.39
- Support$163.01−1.44%2 touches, last on October 27, 2026
- Support$156.91−5.13%3 touches, last on October 8, 2026
- Support$151.32−8.51%3 touches, last on July 28, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 1.22
- Volatility (60 sessions, annualised)
- 48.9%
- Largest fall in the last year
- −40.28%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Repligen: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Repligen has been January: +9.16% on average, positive in 23 years out of 36. The weakest has been September: −3.68% on average, positive in 14 years out of 37. November, the current month, has been positive in 16 years out of 36 (+3.16% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +9.16% | +8.15% | 23 of 36 |
| February | +1.38% | −2.32% | 14 of 37 |
| March | +2.92% | +1.94% | 19 of 37 |
| April | −0.38% | +0.42% | 19 of 37 |
| May | +4.65% | +3.10% | 21 of 37 |
| June | −0.82% | −0.48% | 18 of 37 |
| July | +3.49% | +2.63% | 20 of 37 |
| August | +5.00% | +3.51% | 24 of 37 |
| September | −3.68% | −0.29% | 14 of 37 |
| October | +4.76% | +0.52% | 19 of 37 |
| November | +3.16% | −1.42% | 16 of 36 |
| December | −1.63% | −3.42% | 15 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Repligen and its competitors
Biologic drug makers, contract manufacturers, diagnostic firms and bench-level researchers make up the customer base of Repligen Corporation, which develops bioprocessing technologies and systems in North America, Europe and the Asia Pacific region. Its offering spans filtration units such as cell retention systems and tangential flow cassettes, chromatography columns used to purify biological drugs, Protein A ligands, cell culture growth factors, ELISA kits, and process analytics instruments that monitor critical production parameters in real time. Products are sold under brands including OPUS, XCell, KrosFlo and SoloVPE.
- Headquarters
- Waltham, United States
- Employees
- 2,000
- Founded
- 1981
- Chief executive
- Olivier Loeillot
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| RepligenRGEN | $10.73B | 8.1% | — | +60.78% |
| AvantorAVTR | $10.46B | 8.0% | 30.9 | +103.35% |
| Align TechnologyALGN | $11.86B | 19.6% | 24.5 | +6.03% |
| Cooper CompaniesCOO | $11.91B | 12.9% | 21.5 | +5.44% |
| AptarGroupATR | $9.12B | 12.4% | 34.4 | +25.58% |
| Baxter InternationalBAX | $13.39B | 7.6% | — | +48.76% |
Same industry or related industries, similar size. Compare Repligen with its competitors · Full profile
